Business

Fresenius Medical Care accelerates the second tranche of its EUR 1 billion share buyback program with around EUR 415 million repurchase planned

Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal disease, will accelerate its share buyback program and start the repurchase of the second tranche. The program – presented during the company's Capital Markets Day on June 17, 2025 – has a total volume of EUR 1 billion. Under the second tranche, the company plans to repurchase its own shares for a total amount of around EUR 415 million from January 12 to May 8, 2026.

articleFresenius Medical Care AgJanuary 9, 20263/company/fresenius-medical-care-ag-and-co-kgaa/news/fresenius-medical-care-accelerates-the-second-tranche-of-its-eur-1-billion-share-buyback-program-with-around-eur-415-million-repurchase-planned
Fresenius Medical Care accelerates the second tranche of its EUR 1 billion share buyback program with around EUR 415 million repurchase planned

About this update from Fresenius Medical Care Ag

[{"type":"list","items":[{"val":[{"type":"text","content":"The second tranche of the share buyback is expected to be executed by May 8, 2026","length":81,"tagName":"p"}]},{"val":[{"type":"text","content":"The share buyback program with a total volume of EUR 1 billion is expected to be completed in less than a year, significantly earlier than originally planned","length":162,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":243,"olType":false},{"type":"text","content":"BAD HOMBURG, Germany, Jan. 9, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal disease, will accelerate its share buyback program and start the repurchase of the second tranche. The program – presented during the company's Capital Markets Day on June 17, 2025 – has a total volume of EUR 1 billion. Under the second tranche, the company plans to repurchase its own shares for a total amount of around EUR 415 million from January 12 to May 8, 2026.","length":539,"tagName":"p"},{"type":"image","alt":"Fresenius Medical Care (PRNewsfoto/Fresenius Medical Care North Am)","displaySize":"","headline":null,"caption":"Fresenius Medical Care (PRNewsfoto/Fresenius Medical Care North Am)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":86,"url":"https://media.zenfs.com/en/prnewswire.com/1ea334d2fed6b92c9bd382003cb7c081"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CAPs.jZA.Pm6wlpD_VdyoQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE1MjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/1ea334d2fed6b92c9bd382003cb7c081","width":400,"height":86}},"href":"https://mma.prnewswire.com/media/655917/FMC_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The first tranche of the company's share buyback program was completed ahead of schedule on December 29, 2025. The share buyback program, which is part of the FME capital allocation framework within the 'FME Reignite' strategy, is expected to be completed significantly earlier than originally planned, in less than a year.","length":335,"tagName":"p"},{"type":"text","content":"Helen Giza, CEO and Chair of the Management Board, said, "The successful acceleration of our EUR 1 billion share buyback program is supported by our strong financial performance and consistent execution against ...

More updates from Fresenius Medical Care Ag

Fresenius Medical Careshare buyback